Guide de travaux pratiques · Axe de l'hormone de croissance
Qu'est-ce que l'IGF-1 LR3 ? Aperçu des recherches sur cet analogue de l'IGF-1 résistant à l'IGFBP
What is IGF-1 LR3? It is an 83-residue recombinant analogue of insulin-like growth factor-1 with a 13-residue N-terminal extension and arginine in place of glutamate at position 3, which together sharply reduce binding to IGF-binding proteins. This guide explains the design, what “long” does and does not mean, and the published findings on potency and receptor binding.
Points clés à retenir
- IGF-1 LR3 has 83 residues (native IGF-1 has 70), formula C400H619N111O115S9 and mass about 9.1 kDa, with the three native disulfide bonds retained.
- Its design lowers affinity for IGF-binding proteins by roughly 1000-fold for IGFBP-3 and IGFBP-4 (Ballard et al., 1993), while receptor binding is reduced about 3-fold (Tomas et al., 1992).
- In rats it was cleared from plasma faster than IGF-1 because it does not associate with plasma binding proteins, so “long” refers to the extension, not to a longer half-life.
- Its main research uses are IGF-1 receptor signalling and cell culture, and it is not an approved medicine.
What is IGF-1 LR3?
So, what is IGF-1 LR3? IGF-1 LR3 (Long R3 IGF-I) is a recombinant analogue of human insulin-like growth factor-1. The variant was described by Francis et al. (1992), who made novel recombinant fusion-protein analogues of IGF-I to assess the relative importance of IGF-binding-protein and receptor binding for enhanced biological potency. In practice it is mostly used as a more potent IGF-1 receptor ligand in cell culture.
À usage exclusivement scientifique. Cette présentation synthétise les résultats publiés issus de recherches en laboratoire et sur des animaux. Baltic Peptides fournit ce composé à des chercheurs qualifiés pour des recherches in vitro et précliniques ; il ne s'agit pas d'un médicament et il n'est pas destiné à un usage humain ou vétérinaire.
Structure chimique et caractéristiques techniques
| Biens immobiliers | Valeur |
|---|---|
| Longueur | 83 residues (native IGF-1: 70) |
| Changes vs IGF-1 | N-terminal extension MFPAMPLSSLFVN plus Glu3→Arg |
| Disulfide bonds | Trois (modèle IGF-1 natif) |
| Formule moléculaire | C400H619N111O115S9 |
| Poids moléculaire | ≈9111.5 Da (average, with three disulfides) |
| Numéro CAS | 946870-92-4 (supplier-listed) |
I confirmed that the 83-residue sequence, with three disulfide bonds, reproduces the formula and mass. The nine sulfur atoms come from six cysteines and three methionines. Because it is a folded protein, a mass check alone cannot show that the disulfides are paired correctly, which is why bioactivity assays are used alongside HPLC and mass spectrometry.
Historique des découvertes et de la recherche
The analogues came from CSIRO laboratories in Adelaide, South Australia, where Francis, Ballard and colleagues studied how IGF-binding proteins limit IGF-I action. In the 1992 rat study from the same group, Tomas et al. found that two analogues that bind poorly to IGFBPs, des(1-3)IGF-I and LR3IGF-I, were about 2.5-fold more potent than IGF-I in dexamethasone-treated rats.
LR3 has since become a standard supplement in serum-free mammalian cell culture, because cells secrete IGFBPs that would otherwise sequester native IGF-1.
Mechanism: IGFBP escape and receptor activation
Binding proteins
IGFBPs sequester IGFs away from the type 1 IGF receptor and can inhibit IGF-stimulated mitogenesis, differentiation and survival, as Firth and Baxter (2002) review. IGF-1 has about 1000-fold higher affinity than LR3IGF-I for IGFBP-3, IGFBP-4 and total rat plasma binding proteins (Ballard et al., 1993).
Receptor binding and the “long” misnomer
Tomas et al. noted that LR3IGF-I binds about 3-fold less well than IGF-I to the type 1 IGF receptor, yet was striking in vivo. Ballard and colleagues found that LR3IGF-I was removed from plasma much more rapidly than IGF-I because it does not associate with plasma IGFBPs. “Long” refers to the extended sequence, so the analogue is more potent in IGFBP-rich settings but shorter-lived in rat plasma.
Principaux domaines de recherche
- IGF-1 receptor signalling: PI3K/Akt/mTOR and Ras/MAPK activation in cell models.
- IGFBP biology: separating receptor-driven from binding-protein-mediated effects by comparison with native IGF-1.
- Cell culture and bioprocessing: serum-free media supplementation.
- Muscle cell biology: myoblast proliferation and differentiation in vitro.
Ce que révèlent réellement les études publiées
| Type de preuve | Ce qui est rapporté |
|---|---|
| Données chimiques | Sequence length, extension, Arg3 change and formula are verifiable. |
| Binding studies | About 1000-fold lower IGFBP-3 and IGFBP-4 affinity and about 3-fold lower receptor affinity than IGF-I. |
| Études sur les rats | About 2.5-fold greater potency than IGF-I in dexamethasone-treated rats (Tomas et al., 1992); faster plasma clearance than IGF-I. |
| Réglementation | Not an approved medicine. The licensed IGF-1 product, mecasermin, is a native-sequence rhIGF-1, according to the supplier product page. |
Potency depends on the system. It is most striking where IGFBPs are abundant and smaller where they are absent.
Limites scientifiques et questions en suspens
- Potency gains are model-dependent and not a statement about outcomes outside experimental systems.
- Proper folding and disulfide pairing cannot be confirmed by mass alone.
- Receptor activation has mitogenic consequences, so experimental concentrations and cell types matter.
- It is not approved as a medicine, and IGF-1 and its analogues are on the WADA Prohibited List according to the supplier product page.
Considérations relatives aux analyses et aux travaux de laboratoire
Intact-mass analysis should show about 9111.5 Da. SDS-PAGE and reverse-phase HPLC check purity, and a receptor-binding or cell-proliferation assay confirms bioactivity, since a protein can be pure but misfolded. Endotoxin matters for cell-culture work. As a folded protein, it is sensitive to freeze-thaw cycling, vigorous agitation and adsorption to plastic at low concentrations.
See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the IGF-1 LR3 product page.
Sources et lectures complémentaires
- Francis G.L. et al. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol 8(3):213-223. DOI
- Tomas F.M. et al. (1992). Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J 282:91-97. PMC full text
- Ballard F.J. et al. (1993). Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogs. Growth Regul 3(1):40-44. PubMed
- Firth S.M. and Baxter R.C. (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23(6):824-854. PubMed
Tous les produits de la gamme « Baltic Peptides » sont destinés exclusivement à la recherche en laboratoire. Il ne s'agit ni de médicaments, ni de compléments alimentaires, ni d'aliments, et ils ne sont pas destinés à être utilisés chez l'homme ou chez l'animal. Cet article résume les recherches publiées à des fins purement pédagogiques et ne décrit aucune utilisation chez l'homme.
FAQ
Questions fréquentes
What is IGF-1 LR3?
What does LR3 stand for?
What is the molecular weight and formula of IGF-1 LR3?
En quoi l'IGF-1 LR3 diffère-t-il de l'IGF-1 natif ?
Does Long R3 mean a longer half-life?
Why is IGF-1 LR3 used in cell culture?
Is IGF-1 LR3 an approved medicine?
Continuez à lire
Lectures complémentaires
IGF-1 LR3
Current batches, formats and the COA for IGF-1 LR3.
What is AOD-9604?
A growth-hormone fragment studied separately from the IGF-1 axis.
Comment lire un peptide COA
The checklist for any certificate of analysis.
Research-grade IGF-1 LR3, tested before it ships
HPLC s indépendantes et résultats de spectrométrie de masse pour chaque lot expédié depuis l'UE.
